Published in Genes (Basel) on April 19, 2017
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science (1991) 12.00
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 11.15
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A (1982) 10.50
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
MYC on the path to cancer. Cell (2012) 8.65
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol (1999) 8.17
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 7.30
MYC oncogenes and human neoplastic disease. Oncogene (1999) 7.28
A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell (2010) 6.00
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell (2002) 5.47
Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27
Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology (2011) 5.06
Alcoholic liver disease. Hepatology (2010) 5.04
Signaling network model of chromatin. Cell (2002) 4.87
Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev (2003) 4.68
Mediation of c-Myc-induced apoptosis by p53. Science (1994) 4.45
Myc and Max proteins possess distinct transcriptional activities. Nature (1992) 4.16
Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell (1993) 4.10
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol (1979) 3.68
A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev (1993) 3.60
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med (2001) 3.51
Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature (1992) 3.43
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A (2000) 3.38
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A (1999) 3.24
The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol (2011) 3.01
Hepatocellular carcinoma and hepatitis C in the United States. Hepatology (2002) 3.00
Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A (2010) 2.91
Max: functional domains and interaction with c-Myc. Genes Dev (1992) 2.88
Alcohol and hepatocellular carcinoma. Gastroenterology (2004) 2.61
Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell (2001) 2.29
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24
Oncogene-induced liver neoplasia in transgenic mice. Oncogene (1989) 2.20
Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: evidence for a second class of transforming genes. Proc Natl Acad Sci U S A (1979) 2.16
Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res (1993) 2.09
A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology (2006) 1.99
Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther (2007) 1.95
Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. Proc Natl Acad Sci U S A (2000) 1.89
Glucose regulation of gene transcription. J Biol Chem (2000) 1.86
miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene (2008) 1.86
microRNAs: small molecules with big roles - C. elegans to human cancer. Biol Cell (2008) 1.82
The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene (1997) 1.81
Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol (2009) 1.79
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70
Genome of avian myelocytomatosis virus MC29: analysis by heteroduplex mapping. Proc Natl Acad Sci U S A (1979) 1.68
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62
c-Myc and cancer metabolism. Clin Cancer Res (2012) 1.60
Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer (2002) 1.59
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res (2008) 1.58
MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res (2006) 1.57
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med (2016) 1.47
Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells. Mol Cell Biol (2004) 1.47
Sequential protooncogene expression during rat liver regeneration. Cancer Res (1986) 1.42
Oncogenes in retroviruses and cells: biochemistry and molecular genetics. Adv Cancer Res (1986) 1.42
Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol (2000) 1.41
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol (2008) 1.38
c-Myc regulates cell size and ploidy but is not essential for postnatal proliferation in liver. Proc Natl Acad Sci U S A (2005) 1.35
c-Myc: linking transformation and genomic instability. Curr Mol Med (2008) 1.35
Max-independent functions of Myc in Drosophila melanogaster. Nat Genet (2008) 1.35
Retroviruses and cancer genes. Adv Cancer Res (1982) 1.34
Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs (2007) 1.33
Molecular mechanisms of hepatic fibrosis and principles of therapy. J Gastroenterol (1997) 1.32
Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis. Diabetes Metab Res Rev (2001) 1.31
Targeting MYC Expression through G-Quadruplexes. Genes Cancer (2010) 1.29
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology (2008) 1.29
A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology (2011) 1.29
The 8q24 gene desert: an oasis of non-coding transcriptional activity. Front Genet (2012) 1.28
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A (2003) 1.27
Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol (2010) 1.22
Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. Biochem Biophys Res Commun (1991) 1.20
Conditional deletion of c-myc does not impair liver regeneration. Cancer Res (2006) 1.19
Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology (1999) 1.19
Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis (2003) 1.18
Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J Formos Med Assoc (1993) 1.15
Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. Hepatology (2009) 1.12
Proto-oncogene expression and growth factors during liver regeneration. Symp Fundam Cancer Res (1986) 1.10
Myc-Is this the oncogene from Hell? Cancer Cell (2002) 1.10
Evidence from transgenic mice that myc regulates hepatic glycolysis. FASEB J (1995) 1.08
Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene (1995) 1.08
Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts. Oncogene (2003) 1.07
Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci (2011) 1.06
c-myc in the hematopoietic lineage is crucial for its angiogenic function in the mouse embryo. Development (2008) 1.05
Coexpression of C-myc and transforming growth factor alfa in the liver promotes early replicative senescence and diminishes regenerative capacity after partial hepatectomy in transgenic mice. Hepatology (1997) 1.02
Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS One (2008) 0.99
Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: A sequential pathological evaluation. J Gastroenterol Hepatol (2003) 0.99
Alcohol and hepatocellular carcinoma: a review and a point of view. World J Gastroenterol (2014) 0.98
E2F1 blocks and c-Myc accelerates hepatic ploidy in transgenic mouse models. Biochem Biophys Res Commun (2003) 0.97
Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Oncotarget (2015) 0.95
Overexpression of c-myc in the liver prevents obesity and insulin resistance. FASEB J (2003) 0.94
Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c-myc by small interfering RNAs. FEBS Lett (2004) 0.93